Biogen Pharmachem Industries L (BSE: BIOGEN.BO) Stock Competitors & Peer Comparison
See BIOGEN.BO's competitors and their performance on the BSE and across the wider stock market.
Peer Comparison Table: Investment - Banking & Investment Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BIOGEN.BO and its BSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIOGEN.BO | ₹0.32 | +3.23% | 288.8M | 32.00 | ₹0.01 | N/A |
| JSWHL.NS | ₹10,865.00 | +1.97% | 120.6B | 82.22 | ₹132.14 | N/A |
| JSWHL.BO | ₹10,857.20 | +1.87% | 120.3B | 82.16 | ₹132.15 | N/A |
| JMFINANCIL.NS | ₹122.05 | -0.11% | 116.8B | 9.71 | ₹12.57 | +2.66% |
| JMFINANCIL.BO | ₹122.05 | +0.08% | 116.8B | 9.71 | ₹12.57 | +2.66% |
| IIFLCAPS.BO | ₹339.60 | +0.12% | 106.4B | 14.41 | ₹23.56 | +0.88% |
| AQFINTECH.BO | ₹1,226.85 | -0.16% | 19.2B | 1095.40 | ₹1.12 | N/A |
| MIIL.BO | ₹724.20 | -0.03% | 15.7B | 1905.79 | ₹0.38 | N/A |
| GCSL.BO | ₹531.90 | +2.24% | 12B | 44.81 | ₹11.87 | +0.13% |
| AKCAPIT.BO | ₹1,750.60 | +0.57% | 11.6B | 16.89 | ₹103.65 | +2.97% |
Stock Comparison
JSW Holdings Limited (NSE: JSWHL.NS)
BIOGEN.BO vs JSWHL.NS Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, JSWHL.NS has a market cap of 120.6B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while JSWHL.NS trades at ₹10,865.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas JSWHL.NS's P/E ratio is 82.22. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to JSWHL.NS's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is less volatile compared to JSWHL.NS. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check JSWHL.NS's competition here
JSW Holdings Limited (BSE: JSWHL.BO)
BIOGEN.BO vs JSWHL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, JSWHL.BO has a market cap of 120.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while JSWHL.BO trades at ₹10,857.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas JSWHL.BO's P/E ratio is 82.16. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to JSWHL.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is less volatile compared to JSWHL.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check JSWHL.BO's competition here
JM Financial Limited (NSE: JMFINANCIL.NS)
BIOGEN.BO vs JMFINANCIL.NS Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, JMFINANCIL.NS has a market cap of 116.8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while JMFINANCIL.NS trades at ₹122.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas JMFINANCIL.NS's P/E ratio is 9.71. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to JMFINANCIL.NS's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to JMFINANCIL.NS. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check JMFINANCIL.NS's competition here
JM Financial Limited (BSE: JMFINANCIL.BO)
BIOGEN.BO vs JMFINANCIL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, JMFINANCIL.BO has a market cap of 116.8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while JMFINANCIL.BO trades at ₹122.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas JMFINANCIL.BO's P/E ratio is 9.71. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to JMFINANCIL.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to JMFINANCIL.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check JMFINANCIL.BO's competition here
IIFL Capital Services Ltd (BSE: IIFLCAPS.BO)
BIOGEN.BO vs IIFLCAPS.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, IIFLCAPS.BO has a market cap of 106.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while IIFLCAPS.BO trades at ₹339.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas IIFLCAPS.BO's P/E ratio is 14.41. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to IIFLCAPS.BO's ROE of +0.12%. Regarding short-term risk, BIOGEN.BO is more volatile compared to IIFLCAPS.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check IIFLCAPS.BO's competition here
Algoquant Fintech Ltd. (BSE: AQFINTECH.BO)
BIOGEN.BO vs AQFINTECH.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, AQFINTECH.BO has a market cap of 19.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while AQFINTECH.BO trades at ₹1,226.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas AQFINTECH.BO's P/E ratio is 1095.40. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to AQFINTECH.BO's ROE of +0.05%. Regarding short-term risk, BIOGEN.BO is more volatile compared to AQFINTECH.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check AQFINTECH.BO's competition here
Meghna Infracon Infrastructure Limited (BSE: MIIL.BO)
BIOGEN.BO vs MIIL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, MIIL.BO has a market cap of 15.7B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while MIIL.BO trades at ₹724.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas MIIL.BO's P/E ratio is 1905.79. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MIIL.BO's ROE of +0.47%. Regarding short-term risk, BIOGEN.BO is more volatile compared to MIIL.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check MIIL.BO's competition here
Gretex Corporate Services Ltd (BSE: GCSL.BO)
BIOGEN.BO vs GCSL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, GCSL.BO has a market cap of 12B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while GCSL.BO trades at ₹531.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas GCSL.BO's P/E ratio is 44.81. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GCSL.BO's ROE of +0.09%. Regarding short-term risk, BIOGEN.BO is less volatile compared to GCSL.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check GCSL.BO's competition here
A. K. Capital Services Limited (BSE: AKCAPIT.BO)
BIOGEN.BO vs AKCAPIT.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, AKCAPIT.BO has a market cap of 11.6B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while AKCAPIT.BO trades at ₹1,750.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas AKCAPIT.BO's P/E ratio is 16.89. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to AKCAPIT.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to AKCAPIT.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check AKCAPIT.BO's competition here
MASTER TRUST LTD. (BSE: MASTERTR.BO)
BIOGEN.BO vs MASTERTR.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, MASTERTR.BO has a market cap of 10.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while MASTERTR.BO trades at ₹84.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas MASTERTR.BO's P/E ratio is 5.30. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MASTERTR.BO's ROE of +0.17%. Regarding short-term risk, BIOGEN.BO is more volatile compared to MASTERTR.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check MASTERTR.BO's competition here
Gyftr Limited (BSE: LKPFIN.BO)
BIOGEN.BO vs LKPFIN.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, LKPFIN.BO has a market cap of 9.5B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while LKPFIN.BO trades at ₹150.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas LKPFIN.BO's P/E ratio is -468.75. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to LKPFIN.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is less volatile compared to LKPFIN.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check LKPFIN.BO's competition here
Systematix Corporate Services Limited (BSE: SYSTMTXC.BO)
BIOGEN.BO vs SYSTMTXC.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SYSTMTXC.BO has a market cap of 8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SYSTMTXC.BO trades at ₹60.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SYSTMTXC.BO's P/E ratio is 3.41. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SYSTMTXC.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SYSTMTXC.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SYSTMTXC.BO's competition here
Aryaman Financial Services Limited (BSE: ARYAMAN.BO)
BIOGEN.BO vs ARYAMAN.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ARYAMAN.BO has a market cap of 7.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ARYAMAN.BO trades at ₹590.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ARYAMAN.BO's P/E ratio is 27.52. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ARYAMAN.BO's ROE of +0.17%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ARYAMAN.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARYAMAN.BO's competition here
Kiran Vyapar Limited (BSE: KIRANVYPAR.BO)
BIOGEN.BO vs KIRANVYPAR.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, KIRANVYPAR.BO has a market cap of 5.5B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while KIRANVYPAR.BO trades at ₹201.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas KIRANVYPAR.BO's P/E ratio is 50.63. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to KIRANVYPAR.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is more volatile compared to KIRANVYPAR.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check KIRANVYPAR.BO's competition here
Unifinz Capital India Limited (BSE: UCIL.BO)
BIOGEN.BO vs UCIL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, UCIL.BO has a market cap of 4.9B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while UCIL.BO trades at ₹110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas UCIL.BO's P/E ratio is -32.40. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to UCIL.BO's ROE of +0.73%. Regarding short-term risk, BIOGEN.BO is more volatile compared to UCIL.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check UCIL.BO's competition here
Aryaman Capital Markets Ltd. (BSE: ARYACAPM.BO)
BIOGEN.BO vs ARYACAPM.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ARYACAPM.BO has a market cap of 4.8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ARYACAPM.BO trades at ₹398.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ARYACAPM.BO's P/E ratio is 17.17. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ARYACAPM.BO's ROE of +0.12%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ARYACAPM.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARYACAPM.BO's competition here
Shriram Asset Management Company Limited (BSE: SRAMSET.BO)
BIOGEN.BO vs SRAMSET.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SRAMSET.BO has a market cap of 4.7B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SRAMSET.BO trades at ₹279.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SRAMSET.BO's P/E ratio is -30.79. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SRAMSET.BO's ROE of -0.15%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SRAMSET.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SRAMSET.BO's competition here
Shardul Securities Limited (BSE: SHARDUL.BO)
BIOGEN.BO vs SHARDUL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SHARDUL.BO has a market cap of 4.7B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SHARDUL.BO trades at ₹53.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SHARDUL.BO's P/E ratio is 6.59. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SHARDUL.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SHARDUL.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SHARDUL.BO's competition here
IM+ Capitals Limited (BSE: IMCAP.BO)
BIOGEN.BO vs IMCAP.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, IMCAP.BO has a market cap of 3.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while IMCAP.BO trades at ₹914.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas IMCAP.BO's P/E ratio is 229.89. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to IMCAP.BO's ROE of +0.29%. Regarding short-term risk, BIOGEN.BO is less volatile compared to IMCAP.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check IMCAP.BO's competition here
P.H. Capital Limited (BSE: PHCAP.BO)
BIOGEN.BO vs PHCAP.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, PHCAP.BO has a market cap of 3.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while PHCAP.BO trades at ₹1,034.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas PHCAP.BO's P/E ratio is 41.30. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PHCAP.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is more volatile compared to PHCAP.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check PHCAP.BO's competition here
Onesource Ideas Venture Limited (BSE: OIVL.BO)
BIOGEN.BO vs OIVL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, OIVL.BO has a market cap of 3.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while OIVL.BO trades at ₹5.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas OIVL.BO's P/E ratio is 9.39. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to OIVL.BO's ROE of +0.44%. Regarding short-term risk, BIOGEN.BO is less volatile compared to OIVL.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check OIVL.BO's competition here
Alacrity Securities Limited (BSE: ALSL.BO)
BIOGEN.BO vs ALSL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ALSL.BO has a market cap of 3.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ALSL.BO trades at ₹66.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ALSL.BO's P/E ratio is 49.70. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ALSL.BO's ROE of +0.08%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ALSL.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ALSL.BO's competition here
Regency Fincorp Limited (BSE: REGENCY.BO)
BIOGEN.BO vs REGENCY.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, REGENCY.BO has a market cap of 3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while REGENCY.BO trades at ₹42.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas REGENCY.BO's P/E ratio is 29.04. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to REGENCY.BO's ROE of +0.12%. Regarding short-term risk, BIOGEN.BO is less volatile compared to REGENCY.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check REGENCY.BO's competition here
Quest Capital Markets Ltd. (BSE: QUESTCAP.BO)
BIOGEN.BO vs QUESTCAP.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, QUESTCAP.BO has a market cap of 2.7B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while QUESTCAP.BO trades at ₹266.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas QUESTCAP.BO's P/E ratio is 12.01. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to QUESTCAP.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to QUESTCAP.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check QUESTCAP.BO's competition here
Nidhi Granites Limited (BSE: NIDHGRN.BO)
BIOGEN.BO vs NIDHGRN.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, NIDHGRN.BO has a market cap of 2.6B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while NIDHGRN.BO trades at ₹325.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas NIDHGRN.BO's P/E ratio is 33.94. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to NIDHGRN.BO's ROE of +0.41%. Regarding short-term risk, BIOGEN.BO is less volatile compared to NIDHGRN.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check NIDHGRN.BO's competition here
IL&FS Investment Managers Ltd. (BSE: IVC.BO)
BIOGEN.BO vs IVC.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, IVC.BO has a market cap of 2.6B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while IVC.BO trades at ₹8.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas IVC.BO's P/E ratio is 67.65. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to IVC.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to IVC.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check IVC.BO's competition here
IL&FS Investment Managers Limited (NSE: IVC.NS)
BIOGEN.BO vs IVC.NS Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, IVC.NS has a market cap of 2.6B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while IVC.NS trades at ₹8.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas IVC.NS's P/E ratio is 67.24. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to IVC.NS's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is more volatile compared to IVC.NS. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check IVC.NS's competition here
Hampton Sky Realty Ltd. (BSE: HAMPTON.BO)
BIOGEN.BO vs HAMPTON.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, HAMPTON.BO has a market cap of 2.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while HAMPTON.BO trades at ₹8.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas HAMPTON.BO's P/E ratio is -275.17. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to HAMPTON.BO's ROE of -0.09%. Regarding short-term risk, BIOGEN.BO is less volatile compared to HAMPTON.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check HAMPTON.BO's competition here
Swastika Investmart Limited (BSE: SWASTIKA.BO)
BIOGEN.BO vs SWASTIKA.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SWASTIKA.BO has a market cap of 2.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SWASTIKA.BO trades at ₹111.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SWASTIKA.BO's P/E ratio is 6.98. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SWASTIKA.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SWASTIKA.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SWASTIKA.BO's competition here
Visco Trade Associates Limited (BSE: VISCO.BO)
BIOGEN.BO vs VISCO.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, VISCO.BO has a market cap of 2.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while VISCO.BO trades at ₹92.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas VISCO.BO's P/E ratio is 7.50. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to VISCO.BO's ROE of -0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to VISCO.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check VISCO.BO's competition here
Crescentis Capital Limited (BSE: SODFC.BO)
BIOGEN.BO vs SODFC.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SODFC.BO has a market cap of 2.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SODFC.BO trades at ₹124.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SODFC.BO's P/E ratio is -1782.86. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SODFC.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SODFC.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SODFC.BO's competition here
Pro Fin Capital Services Ltd. (BSE: PROFINC.BO)
BIOGEN.BO vs PROFINC.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, PROFINC.BO has a market cap of 1.8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while PROFINC.BO trades at ₹2.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas PROFINC.BO's P/E ratio is 84.86. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PROFINC.BO's ROE of -0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to PROFINC.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check PROFINC.BO's competition here
Jhaveri Credits and Capital Limited (BSE: JHACC.BO)
BIOGEN.BO vs JHACC.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, JHACC.BO has a market cap of 1.8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while JHACC.BO trades at ₹183.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas JHACC.BO's P/E ratio is 34.71. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to JHACC.BO's ROE of +0.05%. Regarding short-term risk, BIOGEN.BO is less volatile compared to JHACC.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check JHACC.BO's competition here
Credent Global Finance Ltd. (BSE: CGFL.BO)
BIOGEN.BO vs CGFL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, CGFL.BO has a market cap of 1.7B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while CGFL.BO trades at ₹33.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas CGFL.BO's P/E ratio is 7.00. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to CGFL.BO's ROE of +0.26%. Regarding short-term risk, BIOGEN.BO is less volatile compared to CGFL.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check CGFL.BO's competition here
Upsurge Investment & Finance Ltd. (BSE: UPSURGE.BO)
BIOGEN.BO vs UPSURGE.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, UPSURGE.BO has a market cap of 1.5B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while UPSURGE.BO trades at ₹66.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas UPSURGE.BO's P/E ratio is 40.53. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to UPSURGE.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to UPSURGE.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check UPSURGE.BO's competition here
Indus Finance Limited (BSE: INDUSFINL.BO)
BIOGEN.BO vs INDUSFINL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, INDUSFINL.BO has a market cap of 1.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while INDUSFINL.BO trades at ₹154.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas INDUSFINL.BO's P/E ratio is 77.28. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to INDUSFINL.BO's ROE of +0.09%. Regarding short-term risk, BIOGEN.BO is less volatile compared to INDUSFINL.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check INDUSFINL.BO's competition here
Arihant Capital Markets Limited (BSE: ARIHCAPM.BO)
BIOGEN.BO vs ARIHCAPM.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ARIHCAPM.BO has a market cap of 1.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ARIHCAPM.BO trades at ₹68.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ARIHCAPM.BO's P/E ratio is 8.17. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ARIHCAPM.BO's ROE of +0.05%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ARIHCAPM.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARIHCAPM.BO's competition here
Keynote Financial Services Lim (BSE: KEYFINSERV.BO)
BIOGEN.BO vs KEYFINSERV.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, KEYFINSERV.BO has a market cap of 1.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while KEYFINSERV.BO trades at ₹256.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas KEYFINSERV.BO's P/E ratio is 14.58. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to KEYFINSERV.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is more volatile compared to KEYFINSERV.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check KEYFINSERV.BO's competition here
Dharni Capital Services Ltd. (BSE: DHARNI.BO)
BIOGEN.BO vs DHARNI.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, DHARNI.BO has a market cap of 1.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while DHARNI.BO trades at ₹65.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas DHARNI.BO's P/E ratio is 46.43. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to DHARNI.BO's ROE of +0.19%. Regarding short-term risk, BIOGEN.BO is more volatile compared to DHARNI.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check DHARNI.BO's competition here
LKP Securities Limited (BSE: LKPSEC.BO)
BIOGEN.BO vs LKPSEC.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, LKPSEC.BO has a market cap of 1.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while LKPSEC.BO trades at ₹16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas LKPSEC.BO's P/E ratio is 22.54. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to LKPSEC.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is less volatile compared to LKPSEC.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check LKPSEC.BO's competition here
Sunshine Capital Limited (BSE: SCL.BO)
BIOGEN.BO vs SCL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SCL.BO has a market cap of 1.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SCL.BO trades at ₹0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SCL.BO's P/E ratio is 3.83. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SCL.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SCL.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SCL.BO's competition here
Aarnav Fashions Ltd. (BSE: AARNAV.BO)
BIOGEN.BO vs AARNAV.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, AARNAV.BO has a market cap of 1.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while AARNAV.BO trades at ₹28.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas AARNAV.BO's P/E ratio is 88.39. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to AARNAV.BO's ROE of +0.05%. Regarding short-term risk, BIOGEN.BO is less volatile compared to AARNAV.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check AARNAV.BO's competition here
Vibrant Global Capital Ltd (BSE: VGCL.BO)
BIOGEN.BO vs VGCL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, VGCL.BO has a market cap of 1.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while VGCL.BO trades at ₹51.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas VGCL.BO's P/E ratio is 17.27. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to VGCL.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to VGCL.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check VGCL.BO's competition here
Pioneer Investcorp Limited (BSE: PIONRINV.BO)
BIOGEN.BO vs PIONRINV.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, PIONRINV.BO has a market cap of 1.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while PIONRINV.BO trades at ₹94.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas PIONRINV.BO's P/E ratio is 33.30. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PIONRINV.BO's ROE of +0.10%. Regarding short-term risk, BIOGEN.BO is less volatile compared to PIONRINV.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check PIONRINV.BO's competition here
Escorp Asset Management Limite (BSE: ESCORP.BO)
BIOGEN.BO vs ESCORP.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ESCORP.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ESCORP.BO trades at ₹102.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ESCORP.BO's P/E ratio is 38.40. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ESCORP.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ESCORP.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ESCORP.BO's competition here
Supra Pacific Financial Services Ltd (BSE: SUPRAPFSL.BO)
BIOGEN.BO vs SUPRAPFSL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SUPRAPFSL.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SUPRAPFSL.BO trades at ₹33.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SUPRAPFSL.BO's P/E ratio is 13.58. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SUPRAPFSL.BO's ROE of +0.09%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SUPRAPFSL.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SUPRAPFSL.BO's competition here
Naysaa Securities Limited (BSE: NAYSAA.BO)
BIOGEN.BO vs NAYSAA.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, NAYSAA.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while NAYSAA.BO trades at ₹307.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas NAYSAA.BO's P/E ratio is 379.26. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to NAYSAA.BO's ROE of +0.33%. Regarding short-term risk, BIOGEN.BO is less volatile compared to NAYSAA.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check NAYSAA.BO's competition here
Titan Securities Limited (BSE: TITANSEC.BO)
BIOGEN.BO vs TITANSEC.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, TITANSEC.BO has a market cap of 1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while TITANSEC.BO trades at ₹41.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas TITANSEC.BO's P/E ratio is 8.39. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to TITANSEC.BO's ROE of +0.12%. Regarding short-term risk, BIOGEN.BO is more volatile compared to TITANSEC.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check TITANSEC.BO's competition here
Munoth Capital Market Ltd. (BSE: MUNCAPM.BO)
BIOGEN.BO vs MUNCAPM.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, MUNCAPM.BO has a market cap of 950.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while MUNCAPM.BO trades at ₹103.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas MUNCAPM.BO's P/E ratio is -545.79. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MUNCAPM.BO's ROE of -0.03%. Regarding short-term risk, BIOGEN.BO is more volatile compared to MUNCAPM.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check MUNCAPM.BO's competition here
Asit C. Mehta Financial Services Ltd. (BSE: ASITCFIN.BO)
BIOGEN.BO vs ASITCFIN.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ASITCFIN.BO has a market cap of 944.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ASITCFIN.BO trades at ₹114.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ASITCFIN.BO's P/E ratio is -10.76. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ASITCFIN.BO's ROE of -0.07%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ASITCFIN.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ASITCFIN.BO's competition here
Mukesh Babu Financial Services Ltd. (BSE: MUKESHB.BO)
BIOGEN.BO vs MUKESHB.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, MUKESHB.BO has a market cap of 938.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while MUKESHB.BO trades at ₹134.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas MUKESHB.BO's P/E ratio is -55.64. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MUKESHB.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to MUKESHB.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check MUKESHB.BO's competition here
Assam Entrade Limited (BSE: ASSAMENT.BO)
BIOGEN.BO vs ASSAMENT.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ASSAMENT.BO has a market cap of 923.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ASSAMENT.BO trades at ₹641.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ASSAMENT.BO's P/E ratio is 31.99. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ASSAMENT.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ASSAMENT.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ASSAMENT.BO's competition here
Saumya Consultants Limited (BSE: SAUMYA.BO)
BIOGEN.BO vs SAUMYA.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SAUMYA.BO has a market cap of 842.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SAUMYA.BO trades at ₹122.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SAUMYA.BO's P/E ratio is 23.06. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SAUMYA.BO's ROE of -0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SAUMYA.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SAUMYA.BO's competition here
Chartered Capital and Investment Limited (BSE: CHRTEDCA.BO)
BIOGEN.BO vs CHRTEDCA.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, CHRTEDCA.BO has a market cap of 825M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while CHRTEDCA.BO trades at ₹273.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas CHRTEDCA.BO's P/E ratio is 30.47. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to CHRTEDCA.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to CHRTEDCA.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check CHRTEDCA.BO's competition here
Advik Capital Limited (BSE: ADVIKCA.BO)
BIOGEN.BO vs ADVIKCA.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ADVIKCA.BO has a market cap of 815.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ADVIKCA.BO trades at ₹1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ADVIKCA.BO's P/E ratio is 8.15. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ADVIKCA.BO's ROE of -0.12%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ADVIKCA.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ADVIKCA.BO's competition here
Gowra Leasing and Finance Limited (BSE: GOWRALE.BO)
BIOGEN.BO vs GOWRALE.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, GOWRALE.BO has a market cap of 787.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while GOWRALE.BO trades at ₹101.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas GOWRALE.BO's P/E ratio is 10.72. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GOWRALE.BO's ROE of +0.13%. Regarding short-term risk, BIOGEN.BO is less volatile compared to GOWRALE.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check GOWRALE.BO's competition here
SKP Securities Limited (BSE: SKPSEC.BO)
BIOGEN.BO vs SKPSEC.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SKPSEC.BO has a market cap of 779.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SKPSEC.BO trades at ₹114.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SKPSEC.BO's P/E ratio is 26.02. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SKPSEC.BO's ROE of +0.19%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SKPSEC.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SKPSEC.BO's competition here
Wallfort Financial Services Limited (BSE: WALLFORT.BO)
BIOGEN.BO vs WALLFORT.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, WALLFORT.BO has a market cap of 722.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while WALLFORT.BO trades at ₹74.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas WALLFORT.BO's P/E ratio is -7.39. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to WALLFORT.BO's ROE of -0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to WALLFORT.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check WALLFORT.BO's competition here
Gogia Capital Services Limited (BSE: GOGIACAP.BO)
BIOGEN.BO vs GOGIACAP.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, GOGIACAP.BO has a market cap of 719M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while GOGIACAP.BO trades at ₹113.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas GOGIACAP.BO's P/E ratio is -2.98. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GOGIACAP.BO's ROE of -0.00%. Regarding short-term risk, BIOGEN.BO is more volatile compared to GOGIACAP.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check GOGIACAP.BO's competition here
Royal India Corporation Limited (BSE: ROYALIND.BO)
BIOGEN.BO vs ROYALIND.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ROYALIND.BO has a market cap of 704.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ROYALIND.BO trades at ₹5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ROYALIND.BO's P/E ratio is -3.68. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ROYALIND.BO's ROE of +0.49%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ROYALIND.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ROYALIND.BO's competition here
Elixir Capital Ltd (BSE: ELIXIR.BO)
BIOGEN.BO vs ELIXIR.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ELIXIR.BO has a market cap of 678.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ELIXIR.BO trades at ₹116.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ELIXIR.BO's P/E ratio is 22.32. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ELIXIR.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ELIXIR.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ELIXIR.BO's competition here
Joindre Capital Services Limited (BSE: JOINDRE.BO)
BIOGEN.BO vs JOINDRE.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, JOINDRE.BO has a market cap of 671.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while JOINDRE.BO trades at ₹48.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas JOINDRE.BO's P/E ratio is 37.33. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to JOINDRE.BO's ROE of +0.17%. Regarding short-term risk, BIOGEN.BO is less volatile compared to JOINDRE.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check JOINDRE.BO's competition here
Bampsl Securities Limited (BSE: BAMPSL.BO)
BIOGEN.BO vs BAMPSL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, BAMPSL.BO has a market cap of 671.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while BAMPSL.BO trades at ₹19.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas BAMPSL.BO's P/E ratio is 469.52. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to BAMPSL.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is less volatile compared to BAMPSL.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check BAMPSL.BO's competition here
My Money Securities Ltd. (BSE: MYMONEY.BO)
BIOGEN.BO vs MYMONEY.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, MYMONEY.BO has a market cap of 629M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while MYMONEY.BO trades at ₹37.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas MYMONEY.BO's P/E ratio is 14.98. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MYMONEY.BO's ROE of +0.15%. Regarding short-term risk, BIOGEN.BO is less volatile compared to MYMONEY.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check MYMONEY.BO's competition here
Srestha Finvest Limited (BSE: SRESTHA.BO)
BIOGEN.BO vs SRESTHA.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SRESTHA.BO has a market cap of 597.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SRESTHA.BO trades at ₹0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SRESTHA.BO's P/E ratio is -1.62. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SRESTHA.BO's ROE of -0.05%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SRESTHA.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SRESTHA.BO's competition here
Ladderup Finance Limited (BSE: LADDERUP.BO)
BIOGEN.BO vs LADDERUP.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, LADDERUP.BO has a market cap of 583.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while LADDERUP.BO trades at ₹55.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas LADDERUP.BO's P/E ratio is 66.27. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to LADDERUP.BO's ROE of +0.05%. Regarding short-term risk, BIOGEN.BO is more volatile compared to LADDERUP.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check LADDERUP.BO's competition here
Transwarranty Finance Limited (NSE: TFL.NS)
BIOGEN.BO vs TFL.NS Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, TFL.NS has a market cap of 573.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while TFL.NS trades at ₹10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas TFL.NS's P/E ratio is -40.04. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to TFL.NS's ROE of -0.14%. Regarding short-term risk, BIOGEN.BO is less volatile compared to TFL.NS. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check TFL.NS's competition here
HB Portfolio Limited (BSE: HBPOR.BO)
BIOGEN.BO vs HBPOR.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, HBPOR.BO has a market cap of 571M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while HBPOR.BO trades at ₹53.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas HBPOR.BO's P/E ratio is -24.91. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to HBPOR.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is less volatile compared to HBPOR.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check HBPOR.BO's competition here
Dhanlaxmi Cotex Limited (BSE: DHANCOT.BO)
BIOGEN.BO vs DHANCOT.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, DHANCOT.BO has a market cap of 553.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while DHANCOT.BO trades at ₹115.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas DHANCOT.BO's P/E ratio is 668.24. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to DHANCOT.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is more volatile compared to DHANCOT.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check DHANCOT.BO's competition here
Photon Capital Advisors Limited (BSE: PHOTON.BO)
BIOGEN.BO vs PHOTON.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, PHOTON.BO has a market cap of 508.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while PHOTON.BO trades at ₹328.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas PHOTON.BO's P/E ratio is 63.82. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PHOTON.BO's ROE of +0.13%. Regarding short-term risk, BIOGEN.BO is more volatile compared to PHOTON.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check PHOTON.BO's competition here
Nam Securities Limited (BSE: NAM.BO)
BIOGEN.BO vs NAM.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, NAM.BO has a market cap of 498.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while NAM.BO trades at ₹92.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas NAM.BO's P/E ratio is 370.00. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to NAM.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is more volatile compared to NAM.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check NAM.BO's competition here
SMIFS Capital Markets Limited (BSE: SMIFS.BO)
BIOGEN.BO vs SMIFS.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SMIFS.BO has a market cap of 479.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SMIFS.BO trades at ₹81.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SMIFS.BO's P/E ratio is 41.44. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SMIFS.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SMIFS.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SMIFS.BO's competition here
Bridge Securities Limited (BSE: BRIDGESE.BO)
BIOGEN.BO vs BRIDGESE.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, BRIDGESE.BO has a market cap of 462.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while BRIDGESE.BO trades at ₹14.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas BRIDGESE.BO's P/E ratio is 24.66. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to BRIDGESE.BO's ROE of +0.34%. Regarding short-term risk, BIOGEN.BO is less volatile compared to BRIDGESE.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check BRIDGESE.BO's competition here
Mefcom Capital Markets Limited (BSE: MEFCOMCAP.BO)
BIOGEN.BO vs MEFCOMCAP.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, MEFCOMCAP.BO has a market cap of 457M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while MEFCOMCAP.BO trades at ₹9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas MEFCOMCAP.BO's P/E ratio is 13.46. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MEFCOMCAP.BO's ROE of -0.10%. Regarding short-term risk, BIOGEN.BO is less volatile compared to MEFCOMCAP.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check MEFCOMCAP.BO's competition here
Modern Engineering & Projects Ltd. (BSE: MEAPL.BO)
BIOGEN.BO vs MEAPL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, MEAPL.BO has a market cap of 439.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while MEAPL.BO trades at ₹28.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas MEAPL.BO's P/E ratio is 2.58. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MEAPL.BO's ROE of +0.14%. Regarding short-term risk, BIOGEN.BO is less volatile compared to MEAPL.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check MEAPL.BO's competition here
Sai Capital Ltd. (BSE: SAICAPI.BO)
BIOGEN.BO vs SAICAPI.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SAICAPI.BO has a market cap of 412.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SAICAPI.BO trades at ₹142.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SAICAPI.BO's P/E ratio is 3.29. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SAICAPI.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SAICAPI.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SAICAPI.BO's competition here
Sita Enterprises Limited (BSE: SITAENT.BO)
BIOGEN.BO vs SITAENT.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SITAENT.BO has a market cap of 405.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SITAENT.BO trades at ₹135.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SITAENT.BO's P/E ratio is -131.12. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SITAENT.BO's ROE of +0.26%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SITAENT.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SITAENT.BO's competition here
Twentyfirst Century Management Services Limited (BSE: 21STCENMGM.BO)
BIOGEN.BO vs 21STCENMGM.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, 21STCENMGM.BO has a market cap of 389.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while 21STCENMGM.BO trades at ₹37.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas 21STCENMGM.BO's P/E ratio is -1.63. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to 21STCENMGM.BO's ROE of -0.54%. Regarding short-term risk, BIOGEN.BO is less volatile compared to 21STCENMGM.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check 21STCENMGM.BO's competition here
Shri Niwas Leasing and Finance (BSE: SHRINIWAS.BO)
BIOGEN.BO vs SHRINIWAS.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SHRINIWAS.BO has a market cap of 384.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SHRINIWAS.BO trades at ₹12.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SHRINIWAS.BO's P/E ratio is 0.05. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SHRINIWAS.BO's ROE of -2.97%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SHRINIWAS.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SHRINIWAS.BO's competition here
ISL Consulting Limited (BSE: ISLCONSUL.BO)
BIOGEN.BO vs ISLCONSUL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ISLCONSUL.BO has a market cap of 380.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ISLCONSUL.BO trades at ₹15.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ISLCONSUL.BO's P/E ratio is 20.88. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ISLCONSUL.BO's ROE of -0.16%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ISLCONSUL.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ISLCONSUL.BO's competition here
Kiduja India Limited (BSE: KIDUJA.BO)
BIOGEN.BO vs KIDUJA.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, KIDUJA.BO has a market cap of 362.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while KIDUJA.BO trades at ₹15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas KIDUJA.BO's P/E ratio is 16.25. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to KIDUJA.BO's ROE of -0.10%. Regarding short-term risk, BIOGEN.BO is less volatile compared to KIDUJA.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check KIDUJA.BO's competition here
Pan India Corporation Limited (BSE: PANINDIAC.BO)
BIOGEN.BO vs PANINDIAC.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, PANINDIAC.BO has a market cap of 353.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while PANINDIAC.BO trades at ₹1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas PANINDIAC.BO's P/E ratio is 1031.25. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PANINDIAC.BO's ROE of -0.06%. Regarding short-term risk, BIOGEN.BO is less volatile compared to PANINDIAC.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check PANINDIAC.BO's competition here
Anupam Finserv Ltd (BSE: ANUPAM.BO)
BIOGEN.BO vs ANUPAM.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ANUPAM.BO has a market cap of 353M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ANUPAM.BO trades at ₹1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ANUPAM.BO's P/E ratio is 18.60. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ANUPAM.BO's ROE of +0.07%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ANUPAM.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ANUPAM.BO's competition here
Ajcon Global Services Ltd (BSE: AJCON.BO)
BIOGEN.BO vs AJCON.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, AJCON.BO has a market cap of 346.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while AJCON.BO trades at ₹5.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas AJCON.BO's P/E ratio is 6.36. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to AJCON.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to AJCON.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check AJCON.BO's competition here
HB Stockholdings Ltd. (BSE: HBSL.BO)
BIOGEN.BO vs HBSL.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, HBSL.BO has a market cap of 340.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while HBSL.BO trades at ₹49.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas HBSL.BO's P/E ratio is -3.20. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to HBSL.BO's ROE of -0.12%. Regarding short-term risk, BIOGEN.BO is less volatile compared to HBSL.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check HBSL.BO's competition here
Gold Line International Finvest Limited (BSE: GOLDLINE.BO)
BIOGEN.BO vs GOLDLINE.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, GOLDLINE.BO has a market cap of 317.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while GOLDLINE.BO trades at ₹0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas GOLDLINE.BO's P/E ratio is 610.00. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GOLDLINE.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is less volatile compared to GOLDLINE.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check GOLDLINE.BO's competition here
Sumedha Fiscal Services Limited (BSE: SUMEDHA.BO)
BIOGEN.BO vs SUMEDHA.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SUMEDHA.BO has a market cap of 307.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SUMEDHA.BO trades at ₹37.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SUMEDHA.BO's P/E ratio is 12.71. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SUMEDHA.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SUMEDHA.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SUMEDHA.BO's competition here
S. P. Capital Financing Limited (BSE: SPCAPIT.BO)
BIOGEN.BO vs SPCAPIT.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SPCAPIT.BO has a market cap of 305.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SPCAPIT.BO trades at ₹50.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SPCAPIT.BO's P/E ratio is -11.58. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SPCAPIT.BO's ROE of +0.12%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SPCAPIT.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SPCAPIT.BO's competition here
Cubical Financial Services Limited (BSE: CUBIFIN.BO)
BIOGEN.BO vs CUBIFIN.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, CUBIFIN.BO has a market cap of 301.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while CUBIFIN.BO trades at ₹4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas CUBIFIN.BO's P/E ratio is 92.60. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to CUBIFIN.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to CUBIFIN.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check CUBIFIN.BO's competition here
Arnold Holdings Ltd. (BSE: ARNOLD.BO)
BIOGEN.BO vs ARNOLD.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ARNOLD.BO has a market cap of 291.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ARNOLD.BO trades at ₹12.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ARNOLD.BO's P/E ratio is -4.58. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ARNOLD.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ARNOLD.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARNOLD.BO's competition here
Galactico Corporate Services L (BSE: GALACTICO.BO)
BIOGEN.BO vs GALACTICO.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, GALACTICO.BO has a market cap of 288.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while GALACTICO.BO trades at ₹1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas GALACTICO.BO's P/E ratio is 18.09. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GALACTICO.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to GALACTICO.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check GALACTICO.BO's competition here
Libord Finance Limited (BSE: LIBORDFIN.BO)
BIOGEN.BO vs LIBORDFIN.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, LIBORDFIN.BO has a market cap of 282.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while LIBORDFIN.BO trades at ₹17.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas LIBORDFIN.BO's P/E ratio is -75.15. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to LIBORDFIN.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to LIBORDFIN.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check LIBORDFIN.BO's competition here
Ramsons Projects Ltd. (BSE: RAMSONS.BO)
BIOGEN.BO vs RAMSONS.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, RAMSONS.BO has a market cap of 279.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while RAMSONS.BO trades at ₹93.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas RAMSONS.BO's P/E ratio is 3.70. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to RAMSONS.BO's ROE of +0.41%. Regarding short-term risk, BIOGEN.BO is less volatile compared to RAMSONS.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check RAMSONS.BO's competition here
Sulabh Engineers & Services Limited (BSE: SULABEN.BO)
BIOGEN.BO vs SULABEN.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, SULABEN.BO has a market cap of 273.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while SULABEN.BO trades at ₹2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas SULABEN.BO's P/E ratio is 173.25. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to SULABEN.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SULABEN.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SULABEN.BO's competition here
G.S.B. Finance Limited (BSE: GSBFIN.BO)
BIOGEN.BO vs GSBFIN.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, GSBFIN.BO has a market cap of 267.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while GSBFIN.BO trades at ₹44.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas GSBFIN.BO's P/E ratio is -375.13. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to GSBFIN.BO's ROE of -0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to GSBFIN.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check GSBFIN.BO's competition here
Purshottam Investofin Ltd (BSE: PURSHOTTAM.BO)
BIOGEN.BO vs PURSHOTTAM.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, PURSHOTTAM.BO has a market cap of 265.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while PURSHOTTAM.BO trades at ₹35.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas PURSHOTTAM.BO's P/E ratio is -14.77. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to PURSHOTTAM.BO's ROE of -0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to PURSHOTTAM.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check PURSHOTTAM.BO's competition here
Madhusudan Securities Limited (BSE: MADHUSE.BO)
BIOGEN.BO vs MADHUSE.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, MADHUSE.BO has a market cap of 265.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while MADHUSE.BO trades at ₹17.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas MADHUSE.BO's P/E ratio is 13.10. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to MADHUSE.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to MADHUSE.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check MADHUSE.BO's competition here
Abhishek Finlease Limited (BSE: ABHIFIN.BO)
BIOGEN.BO vs ABHIFIN.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, ABHIFIN.BO has a market cap of 260.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while ABHIFIN.BO trades at ₹56.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas ABHIFIN.BO's P/E ratio is 260.06. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to ABHIFIN.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ABHIFIN.BO. This indicates lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ABHIFIN.BO's competition here
Stanrose Mafatlal Investments and Finance Limited (BSE: STANROS.BO)
BIOGEN.BO vs STANROS.BO Comparison July 2026
Biogen Pharmachem Industries L (BSE: BIOGEN.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGEN.BO stands at 288.8M. In comparison, STANROS.BO has a market cap of 257.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.32 on the BSE, while STANROS.BO trades at ₹64.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGEN.BO currently has a P/E ratio of 32.00, whereas STANROS.BO's P/E ratio is -10.05. In terms of profitability, BIOGEN.BO's ROE is +0.01%, compared to STANROS.BO's ROE of -0.08%. Regarding short-term risk, BIOGEN.BO is more volatile compared to STANROS.BO. This indicates higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check STANROS.BO's competition here